Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for...
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project
STOCKHOLM, Sweden and COPENHAGEN, Denmark - November 20, 2008. Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for...
HOUSTON & LAS VEGAS--(BUSINESS WIRE)--Nov 20, 2008 - Several thought leaders from the Burzynski Research Institute, Inc. (BRI) and the Burzynski Clinic (BC) in Houston, Texas are presenting at the 13th Annual Scientific Meeting of the Society...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2008 - Gloucester Pharmaceuticals today announced four presentations from clinical trials of romidepsin at the upcoming 50th American Society of Hematology (ASH) Annual Meeting being held in San Francisco,...
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Nov 20, 2008 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its phase 2 melanoma study, Professor...
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Nov 20, 2008 - Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that its scientists recently made several...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented new pre-clinical data from its TTR amyloidosis development program at Cambridge...
Novel Antimicrobial Drug Demonstrates Ultra-Rapid Effectiveness Against Broad Range of Drug-Resistant Pathogens
TROMSO, Norway, November 20, 2008 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma has announced results...
ISELIN, N.J., November 19, 2008/PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 19, 2008 - KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain...
LILLE (France), CAMBRIDGE (Mass.), Nov. 18, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of...
- Improvements in Motor Function Maintained at Six Months -
- Data to be Presented at 38th Annual Meeting of Society for Neuroscience -
OXFORD, England, Nov. 19, 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today...
TSX: BMR
TORONTO, November 19, 2008 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it will be presenting an...
LONDON, Nov. 19, 2008-AstraZeneca today announced results from three Phase III studies of ZACTIMA (vandetanib) in combination with chemotherapy agents docetaxel (ZODIAC) and pemetrexed (ZEAL) and as monotherapy (ZEST) in non-small cell lung cancer...
HYDERABAD, INDIA (Nov 18, 2008) – Several data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Neuroscience 2008 meeting being held at Washington DC, USA during...
AURORA, Ontario, November 19, 2008 /PRNewswire/ -- Helix BioPharma Corp. today announced that it will present preclinical data about the mechanism of action for L-DOS47, the first drug candidate under development based on the Company's...
SAN DIEGO--(BUSINESS WIRE)--Nov 19, 2008 - Results of a new peer-reviewed study published online in the journal Free Radical Biology and Medicine clearly demonstrates that the synergistic impact of the active ingredients used in the formulation of...
NEW YORK--(BUSINESS WIRE)--Nov 19, 2008 - Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, will present new efficacy data from Phase 1 and 2 clinical trials of...
Company Expects Release of Preliminary Top-line Data from the First Phase III Clinical Trial of JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
PALO ALTO, Calif., November 19, 2008 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc....
SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa--(BUSINESS WIRE)--Nov 19, 2008 - Titan Pharmaceuticals, Inc. (AMEX:TTP) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the treatment of...
More...
